이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Biotest 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Peter Janssen

최고 경영자

€926.0k

총 보상

CEO 급여 비율	47.5%
CEO 임기	1.8yrs
CEO 소유권	n/a
경영진 평균 재임 기간	2.5yrs
이사회 평균 재임 기간	2.2yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Peter Janssen 의 보수는 Biotest 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	€177m
Dec 31 2023	€926k	€440k	€127m
Sep 30 2023	n/a	n/a	€91m
Jun 30 2023	n/a	n/a	-€38m
Mar 31 2023	n/a	n/a	-€47m
Dec 31 2022	€333k	€147k	-€32m

보상 대 시장: Peter 의 총 보상 ($USD 995.06K ) German 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 1.53M ).

보상과 수익: Peter 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Peter Janssen (56 yo)

1.8yrs

테뉴어

€926,000

보상

Mr. Peter Janssen serves as Member of Management Board for Biotest Aktiengesellschaft since September 1, 2022 and served as its Chief Operating Officer since September 2022 until January 2024. He has been...

리더십 팀

이름	위치	테뉴어	보상	소유권
Peter Janssen	CEO & Chairman of the Board of Management	1.8yrs	€926.00k	데이터 없음
Ainhoa Zubiaga	Member of Management Board & CFO	1.4yrs	€605.00k	데이터 없음
Jorg Schuttrumpf	Chief Scientific Officer & Member of the Management Board	2.5yrs	€707.00k	데이터 없음
Dirk Schuck	Member of Supervisory Board	2.5yrs	€44.00k	데이터 없음
Monika Buttkereit	Head of Investor Relations	no data	데이터 없음	데이터 없음
Christina Erb	Head of Corporate HR	8.9yrs	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

50.5yo

평균 연령

경험이 풍부한 관리: BIO3 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Dirk Schuck	Member of Supervisory Board	2.2yrs	€44.00k	데이터 없음
Uta Kemmerich-Keil	Member of Supervisory Board	2.2yrs	€55.00k	데이터 없음
Raimon Grifols Roura	Member of Supervisory Board	1.2yrs	€29.00k	데이터 없음
Bernhard R. Ehmer	Chairman of the Supervisory Board	2.2yrs	€132.00k	데이터 없음
David Bell	Member of Supervisory Board	2.1yrs	€44.00k	데이터 없음
Jurgen Heilmann	Employee Representative Member of Supervisory Board	12.8yrs	€44.00k	데이터 없음

2.2yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: BIO3 의 이사회는 경험(평균 재직 기간 2.1 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Biotest 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024

Biotest AG Appoints Peter Janssen as Chairman of the Management Board, Effective from January 1, 2024

Biotest AG Appoints Ainhoa Mendizabal as CFO, with Effect from 15 February, 2023

Biotest AG Announces Board Changes

Recent updates

Biotest Receives FDA Approval for Innovative Yimmugo Immunoglobulin to Treat Primary Immunodeficiencies

First quarter 2024 earnings released: EPS: €0.74 (vs €0.53 loss in 1Q 2023)

Upcoming dividend of €0.08 per share

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues exceed analyst expectations

Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024

Biotest Aktiengesellschaft to Report First Half, 2024 Results on Jul 30, 2024

Biotest Aktiengesellschaft to Report Fiscal Year 2023 Results on Mar 28, 2024

Third quarter 2023 earnings released

Biotest Aktiengesellschaft Raises Earnings Guidance for the Year 2023

Biotest AG Appoints Peter Janssen as Chairman of the Management Board, Effective from January 1, 2024

New major risk - Financial position

Biotest Treats First Patient with Severe Community- Acquired Pneumonia in Phase III Trial with Trimodulin

Biotest AG Announces US Food and Drug Administration Accepts Marketing Authorization Application for Immunoglobulin Yimmugo

Second quarter 2023 earnings released: EPS: €0.55 (vs €0.39 loss in 2Q 2022)

First quarter 2023 earnings released

Full year 2022 earnings: Revenues miss analyst expectations

Now 20% undervalued after recent price drop

Biotest AG Appoints Ainhoa Mendizabal as CFO, with Effect from 15 February, 2023

Biotest Aktiengesellschaft to Report Fiscal Year 2022 Results on Mar 23, 2023

Third quarter 2022 earnings released

No longer forecast to breakeven

Second quarter 2022 earnings released: €0.39 loss per share (vs €0.11 loss in 2Q 2021)

Biotest AG Conducts Clinical Phase III Study PreCyssion with Cmv Hyperimmunoglobulin (Cytotect CP Biotest-) for the Prevention of CMV Infection in the Unborn Child in Germany

Biotest AG Achieves Important Milestone in Phase III Study in Acquired Fibrinogen Deficiency

First quarter 2022 earnings: Revenues in line with analyst expectations

Biotest AG Announces Board Changes

Upcoming dividend of €0.04 per share

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.

Biotest Submits Marketing Authorisation Application for IgG Next Generation

Consensus forecasts updated

Biotest AG Announces Biotest Treats First CMV-Positive Pregnant Woman in Phase III Clinical Trial to Prevent Transmission of CMV Infection to the Unborn Child

Consensus forecasts updated

Biotest AG Accelerates Trimodulin Development in Hospitalized Covid-19 Patients with Federal Funding from the German Ministries of Health, and Education & Research

Price target increased to €38.93

Third quarter 2021 earnings released

Biotest Receives Approval for Phase III Clinical Trial in Pregnant Women for Prevention of CMV Infection of the Unborn Baby

Biotest Announces the Outcome for Its ESsCOVID (Escape from Severe COVID-19) Trial in Patients with Severe COVID-19

Second quarter 2021 earnings released: €0.11 loss per share (vs €0.16 loss in 2Q 2020)

Biotest AG Provides Earnings Guidance for the Year 2021

Biotest AG Successfully Completes Recruitment for Its Clinical Trial with Trimodulin in Severe Covid-19 Patients

First quarter 2021 earnings released: €0.37 loss per share (vs €0.28 loss in 1Q 2020)

Upcoming dividend of €0.04 per share

Full year 2020 earnings released: €0.80 loss per share (vs €0.13 loss in FY 2019)

Consensus forecasts updated

Biotest Aktiengesellschaft Provides Earnings Guidance for the Year 2021

Biotest AG Supports Clinical Study with Pentaglobin(R) in Covid-19 at the University Hospital Akh Vienna

Biotest AG Revised Earnings Guidance for the Fiscal Year 2020

New 90-day high: €28.80

Biotest Aktiengesellschaft to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: €28.50

Biotest Aktiengesellschaft Announces Approval of Biotest Aktiengesellschaft for the Treatment of Severe Bacterial Infections with Concomitant Use of Antibiotics

Biotest Aktiengesellschaft to Report Q1, 2021 Results on May 11, 2021

Third quarter 2020 earnings released: €0.39 loss per share

Analysts update estimates

New 90-day high - €24.90

First half earnings released

New 90-day high - €22.30

New 90-day high - €21.30

Biotest Aktiengesellschaft to Report Q2, 2020 Results on Aug 13, 2020

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령